Date: 2017-08-29
Type of information: Research agreement
Compound: antibody drug conjugate therapy for cancer against the vascular target TM4SF1
Company: Merck KGaA (Germany) Angiex (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
- antibody drug conjugate. This antibody drug conjugate is directed against the vascular target TM4SF1 (Transmembrane 4 L Six Family Member 1). The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. It is highly expressed in different carcinomas.
functions in growth, motility, invasion, and metastasis of tumor cells. It regulates angiogenesis by endothelial cells.
Disease:
Details:
- • On August 29, 2017, Merck KGaA announced a new collaboration with Angiex to support the biotechnology start-up’s ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.
The collaboration with Angiex is the first project to be undertaken at Merck KGaA’s new biodevelopment center in Massachusetts. Merck KGaA will give Angiex access to endto-end process development tools, education programs and training to support its success. These solutions include BioReliance® End-to-End Solutions that deliver products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance® End-to-End Solutions, Merck KGaA will inaugurate its new biodevelopment center in Burlington, Massachusetts in October 2017.
Financial terms:
Latest news:
Is general: Yes
